FDA Concerned About Study On Risks Of Chantix
By Emily Field ( September 12, 2016, 7:23 PM EDT) -- U.S. Food and Drug Administration staff voiced concerns with a how study handled adverse events on Monday in advance of a meeting to consider whether or not a black box warning label for suicidal ideation and other psychiatric risks on Pfizer Inc.'s smoking cessation drug Chantix should be removed....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.